Several genetic alterations in breast and glioma tumor samples were identified [81,83], including two Claspin germline mutations and co-segregation of three polymorphisms in patients with breast cancer, which led to loss of Claspin expression in tumor cells [84], and in familial breast, breast-ovarian, and pancreatic cancer [82,85]. Here, CLSPN is linked to pancreatic neoplasm.